Free Trial

Trevena (TRVN) Competitors

Trevena logo
$0.94 -0.05 (-5.50%)
As of 07/11/2025 12:43 PM Eastern

TRVN vs. LIPO, PALI, ONVO, ADIL, WINT, GENE, EVAX, PPBT, ZVSA, and ENVB

Should you be buying Trevena stock or one of its competitors? The main competitors of Trevena include Lipella Pharmaceuticals (LIPO), Palisade Bio (PALI), Organovo (ONVO), Adial Pharmaceuticals (ADIL), Windtree Therapeutics (WINT), Genetic Technologies (GENE), Evaxion A/S (EVAX), Purple Biotech (PPBT), ZyVersa Therapeutics (ZVSA), and Enveric Biosciences (ENVB). These companies are all part of the "pharmaceutical products" industry.

Trevena vs. Its Competitors

Trevena (NASDAQ:TRVN) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.

Trevena presently has a consensus price target of $5.00, indicating a potential upside of 434.64%. Given Trevena's stronger consensus rating and higher possible upside, analysts plainly believe Trevena is more favorable than Lipella Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trevena
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Lipella Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Trevena had 1 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 1 mentions for Trevena and 0 mentions for Lipella Pharmaceuticals. Trevena's average media sentiment score of 1.08 beat Lipella Pharmaceuticals' score of 0.00 indicating that Trevena is being referred to more favorably in the media.

Company Overall Sentiment
Trevena Positive
Lipella Pharmaceuticals Neutral

Lipella Pharmaceuticals has higher revenue and earnings than Trevena. Lipella Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevena, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K2.02-$40.29M-$47.04-0.02
Lipella Pharmaceuticals$536.36K6.25-$5.02M-$4.08-0.18

Trevena has a net margin of 0.00% compared to Lipella Pharmaceuticals' net margin of -988.83%. Trevena's return on equity of 0.00% beat Lipella Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Lipella Pharmaceuticals -988.83%-224.08%-172.88%

13.6% of Trevena shares are owned by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are owned by institutional investors. 2.7% of Trevena shares are owned by company insiders. Comparatively, 32.1% of Lipella Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Trevena has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of -0.08, meaning that its share price is 108% less volatile than the S&P 500.

Summary

Trevena beats Lipella Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Trevena News Delivered to You Automatically

Sign up to receive the latest news and ratings for TRVN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TRVN vs. The Competition

MetricTrevenaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$897K$838.34M$5.56B$9.10B
Dividend YieldN/A4.84%5.06%4.02%
P/E Ratio-0.021.3828.2620.26
Price / Sales2.02241.37427.70153.06
Price / CashN/A17.6937.1257.67
Price / Book-0.086.588.045.49
Net Income-$40.29M-$23.83M$3.19B$250.45M
7 Day Performance-0.51%1.59%3.62%4.79%
1 Month Performance-8.31%-0.08%5.98%9.59%
1 Year Performance-84.48%4.35%29.39%16.41%

Trevena Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TRVN
Trevena
1.7042 of 5 stars
$0.94
-5.5%
$5.00
+434.6%
-84.5%$897K$443K-0.0240Positive News
Gap Down
LIPO
Lipella Pharmaceuticals
1.6291 of 5 stars
$0.85
+9.1%
N/A-79.6%$3.49M$536.36K-0.214
PALI
Palisade Bio
2.721 of 5 stars
$0.73
+1.2%
$12.00
+1,534.9%
-83.4%$3.48M$250K-0.1110News Coverage
ONVO
Organovo
N/AN/AN/AN/A$3.47M$122K-2.4020Gap Up
ADIL
Adial Pharmaceuticals
2.5266 of 5 stars
$0.33
-0.4%
$8.00
+2,357.0%
-65.9%$3.41MN/A-0.2220News Coverage
Gap Down
WINT
Windtree Therapeutics
3.153 of 5 stars
$0.80
-14.1%
$350.00
+43,759.6%
-99.6%$3.40MN/A0.0030Positive News
High Trading Volume
GENE
Genetic Technologies
N/A$0.77
flat
N/AN/A$3.37M$7.66M0.0050High Trading Volume
EVAX
Evaxion A/S
2.8175 of 5 stars
$2.30
-3.8%
$10.00
+334.8%
-83.9%$3.35M$3.34M-1.9860News Coverage
PPBT
Purple Biotech
2.1312 of 5 stars
$2.44
-1.6%
$33.00
+1,252.5%
N/A$3.30MN/A-0.9320
ZVSA
ZyVersa Therapeutics
0.1839 of 5 stars
$0.66
-1.4%
N/A-88.0%$3.20MN/A0.002Analyst Upgrade
ENVB
Enveric Biosciences
2.6949 of 5 stars
$1.27
+0.8%
$10.00
+687.4%
-83.1%$3.11MN/A-0.0320

Related Companies and Tools


This page (NASDAQ:TRVN) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners